Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Minisiston · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Minisiston (SH D00342A) | DRUG | Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval |
Inclusion Criteria: * Healthy women requiring contraception Exclusion Criteria: * Pregnant or lactating women, history or suspicion of hormone dependent tumor or any other conditions which forbid the participation.
Minisiston is a small molecule drug used for contraception. It is a low dose combined oral contraceptive being developed by Bayer AG. The drug is intended for use in women aged 18 years and older, as studied in a clinical trial conducted in Germany.
Minisiston is being developed by Bayer AG, a pharmaceutical company traded under the ticker BAYRY. The drug is currently in Phase 3 clinical development for contraception, with one completed trial involving 840 participants.
Minisiston is in Phase 3 clinical development. It is an investigational drug for contraception and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the drug remains under clinical investigation.
Minisiston has one completed Phase 3 clinical trial registered under NCT00220324, titled "Pearl Index Study With Low Dose Combined Oral Contraceptive." The trial enrolled 840 healthy female volunteers aged 18 years and older in Germany, studying the drug for contraception.
Minisiston is a low dose combined oral contraceptive, as indicated by the clinical trial title. It is a small molecule drug being developed for contraception, and the completed Phase 3 study evaluated its Pearl Index, a measure of contraceptive effectiveness.